Actinium Pharmaceuticals $ATNM Further Strengthens IP Portfolio: Memorial Sloan Kettering (MSK)

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or the “Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers paymentdatasystems-650x535 , announced today that the Company has been assigned two provisional patent applications from Memorial Sloan-Kettering Cancer Center (MSK). The Company’s License, Development and Commercialization Agreement (License Agreement) with MSK, which already included issued patents that pertain to Actinium’s Alpha Particle Immunotherapy (APIT) technology platform and drug preparation methods now includes these newly assigned provisional patent applications. Read more